Abstract:Antiphospholipid syndrome (APS) is a systemic autoimmune disease, where persistent presence of antiphospholipid antibodies (aPL) leads to thrombotic and obstetric complications. APS is a paradigmatic thromboinflammatory disease. Thromboinflammation is a pathophysiological mechanism coupling inflammation and thrombosis, which contributes to the pathophysiology of cardiovascular disease. APS can serve as a model to unravel mechanisms of thromboinflammation and the relationship between innate immune cells and thrombosis. Monocytes are activated by aPL into a proinflammatory and procoagulant phenotype, producing proinflammatory cytokines such as tumor necrosis factor α, interleukin 6, as well as tissue factor. Important cellular signaling pathways involved are the NF-κB-pathway, mammalian target of rapamycin (mTOR) signaling, and the NOD-, LRR-, and pyrin domain-containing protein 3 inflammasome. All of these may serve as future therapeutic targets. Neutrophils produce neutrophil extracellular traps in response to aPL, and this leads to thrombosis. Thrombosis in APS also stems from increased interaction of neutrophils with endothelial cells through P-selectin glycoprotein ligand-1. NETosis can be targeted not only with several experimental therapeutics, such as DNase, but also through the redirection of current therapies such as defibrotide and the antiplatelet agent dipyridamole. Activation of platelets by aPL leads to a procoagulant phenotype. Platelet-leukocyte interactions are increased, possibly mediated by increased levels of soluble P-selectin and soluble CD40-ligand. Platelet-directed future treatment options involve the inhibition of several platelet receptors activated by aPL, as well as mTOR inhibition. This review discusses mechanisms underlying thromboinflammation in APS that present targetable therapeutic options, some of which may be generalizable to other thromboinflammatory diseases.

Antiphospholipid syndrome pathogenesis in 2023: an update of new mechanisms or just a reconsideration of the old ones?

Cellular and Molecular Mechanisms of Anti-Phospholipid Syndrome

Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management

An update on inflammation in antiphospholipid syndrome

Advances in the Pathophysiology of Thrombosis in Antiphospholipid Syndrome: Molecular Mechanisms and Signaling through Lipid Rafts

Obstetric antiphospholipid syndrome: A recent classification for an old defined disorder

Antiphospholipid Syndrome in Pregnancy: New and Old Pathogenetic Mechanisms

An Update on Antiphospholipid Syndrome

Targeting thromboinflammation in antiphospholipid syndrome

Platelets and Thrombotic Antiphospholipid Syndrome

Insights into Molecular Mechanisms and Clinical Manifestations

Antiphospholipid antibodies and antiphospholipid syndrome

The Pathophysiology of The Antiphospholipid Syndrome: A Perspective From The Blood Coagulation System

Evolution of Antiphospholipid Syndrome

Risk Factors for Antiphospholipid Antibodies and Antiphospholipid Syndrome

Deciphering the clinical significance of longitudinal antiphospholipid antibody titers

Rethinking antiphospholipid syndrome to guide future management and research

Thrombosis in Antiphospholipid Syndrome: Current Perspectives and Challenges in Laboratory Testing for Antiphospholipid Antibodies

Beta 2 glycoprotein I and neutrophil extracellular traps: Potential bridge between innate and adaptive immunity in anti-phospholipid syndrome

Risk of Thrombosis, Pregnancy Morbidity or Death in Antiphospholipid Syndrome

Lipid-binding antiphospholipid antibodies: significance for pathophysiology and diagnosis of the antiphospholipid syndrome